Effect of glimepiride compared with glibenclamide on post prandial blood sugar in type II diabetes mellitus patients
Keywords:Type II diabetes mellitus, Glimepiride, Glibenclamide, Post prandial blood sugar, Sulfonylureas
Background: Diabetes mellitus is a major public health problem with many complications. The Global Burden of Diabetes Study has projected that there will be a 122% increase in the number of people with diabetes mellitus worldwide in 2025 compared to 1995. Despite the availability of new agents for the treatment of type 2 diabetes mellitus oral sulfonylureas remain a cornerstone of therapy.Glibenclamide and glimepiride are widely used sulfonylurea antidiabetic drugs.
Methods: A randomized, open, parallel group study was conducted by the Department of Pharmacology in association with Department of Medicine at Maharishi Markandeshwar Institute of Medical Sciences & Research (MMIMSR), Mullana, Ambala. Total 50 patients were divided into two groups I & II. In Group I (n=25) glibenclamide (5-15 mg/day) & in Group II (n=25) glimepiride (1-6mg/day) was administered for a period of 24 weeks and data analyzed by Student’s “t”- test.
Results: There was a significant improvement in the post prandial blood sugar score (p<0.05) in both the study groups (I&II) after 24 weeks but post prandial blood level did not differ significantly (p>0.05) between the two groups.
Conclusions: Both the drugs glibenclamide and glimepiride were effectively reduced post prandial blood sugar in both the groups. But these sulfonylurea drugs lowered post prandial blood sugar to a similar degree without significant difference between the two groups.
Bihari Lal Shrivastava SR, Shrivastava PS, Ramasamy J. Role of self-care in management of diabetes mellitus. J Diabetes Metab Disord. 2013;12:14.
Muninarayana C, Balachandra G, Hiremath SG, Iyengar K, Anil NS. Prevalence and awareness regarding diabetes mellitus in rural Tamaka, Kolar. Int J Diabetes Dev Ctries. 2010Jan-Mar;30(1):18–21.
Saumya SM, Mahaboob B. Antioxidant effect of Lagerstroemia specicosapers (Banaba) leaf extract in streptozotocin-induced diabetic mice. Indian J Exp Biol. 2011;49 (2):125.
Mayfield J. Diagnosis and classification of diabetes mellitus: new criteria. Am Fam Physian. 1998 Oct;58(6):1355-62.
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2012;35(1):64-71.
Miller LJ, Salman K, Shulman LH, Rose LI. Bed time insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type 2 diabetes. Clin Pharmacol Ther. 1993Mar;53(3):380- 4.
Aquilante CL. Sulfonylurea pharmacogenomics in type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010Mar;8(3):359–72.
Prashanth S, Kumar AA, Madhu B, Rama N, Sagar JV. Pharmacokinetic and pharmacodynamic drug interactions of carbamazepine and glibenclamide in healthy albino wistar rats. J Pharmacol Pharmacother. 2011Jan-Mar;2(1):7–10.
World health organization: Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World health organization. 1999.
Chuang LM, Tsai ST, Huang BY, Tai TY: The status of diabetes control in Asia–a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med. 2002;19(12):978-85.
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2009Jan;32:67.
Groop L, Wahlinboll E, Groop PH, Totterman KJ, Melander A, Tolppaner EM, et al. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. Eur J Clin Pharmacol. 1985;28(6):697-704.
Skrapari I, Perra D, Ioanndis I, Karabina SA, Elisaf M, Tselepis AD, et al. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels. Diabetic Medicine. 2001Oct;18(10):781-5.
Abdul B, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations. Vascular Health and Risk Management. 2012Aug;8:463-72.